Global Female Infertility Drugs Market 2019-2023
SKU ID :TNV-13783017 | Published Date: 01-Aug-2019 | No. of pages: 129Description
TOC
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY ROA
Market segmentation by RoA
Comparison by RoA
Parenteral - Market size and forecast 2018-2023
Oral - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by RoA
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Increasing awareness about female infertility
Patient assistance programs
Introduction of biosimilars
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Allergan Plc
Ferring BV
Merck KGaA
Novartis AG
Sanofi
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: RoA - Market share 2018-2023 (%)
Exhibit 18: Comparison by RoA
Exhibit 19: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by RoA
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Number of STD cases in US 2017
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Prevalence of infertility in some Indian states
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Some of the health problems associated with the use of ART
Exhibit 46: Pipeline molecules for treatment of female infertility: Overview
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Cost comparison of follitropin alfa
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Allergan Plc - Vendor overview
Exhibit 55: Allergan Plc - Product segments
Exhibit 56: Allergan Plc - Organizational developments
Exhibit 57: Allergan Plc - Geographic focus
Exhibit 58: Allergan Plc - Segment focus
Exhibit 59: Allergan Plc - Key offerings
Exhibit 60: Allergan Plc - Key customers
Exhibit 61: Ferring BV - Vendor overview
Exhibit 62: Ferring BV - Product segments
Exhibit 63: Ferring BV - Organizational developments
Exhibit 64: Ferring BV - Key offerings
Exhibit 65: Ferring BV - Key customers
Exhibit 66: Merck KGaA - Vendor overview
Exhibit 67: Merck KGaA - Business segments
Exhibit 68: Merck KGaA - Organizational developments
Exhibit 69: Merck KGaA - Geographic focus
Exhibit 70: Merck KGaA - Segment focus
Exhibit 71: Merck KGaA - Key offerings
Exhibit 72: Merck KGaA - Key customers
Exhibit 73: Novartis AG - Vendor overview
Exhibit 74: Novartis AG - Business segments
Exhibit 75: Novartis AG - Organizational developments
Exhibit 76: Novartis AG - Geographic focus
Exhibit 77: Novartis AG - Segment focus
Exhibit 78: Novartis AG - Key offerings
Exhibit 79: Novartis AG - Key customers
Exhibit 80: Sanofi - Vendor overview
Exhibit 81: Sanofi - Business segments
Exhibit 82: Sanofi - Organizational developments
Exhibit 83: Sanofi - Geographic focus
Exhibit 84: Sanofi - Segment focus
Exhibit 85: Sanofi - Key offerings
Exhibit 86: Sanofi - Key customers
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: Definition of market positioning of vendors
Tables & Figures
Companies
Allergan Plc, Ferring BV, Merck KGaA, Novartis AG, and Sanofi.
- PRICE
-
$2500$4000